CRISPRMED24
CRISPRMED24 Program - Download pdf.
CRISPRMED24 Abstract Book is now available - Check it here.
CRISPRMED24 Stories from the CMN Community on LinkedIn.
CRISPRMED24 Recording Virtual Event 22nd April - Available on-demand.
 
CRISPRMED24 Recordings In-person Event 23-25 April

 

  • Meet the global CRISPR Medicine/Genomic Medicine community in Copenhagen, Denmark 2024.
  • Focus: Tools, Delivery, Safety/Off-target, Diseases, Pre-clinical/clinical, Standards and Regulations | Functional Genomics, Target Identification, Target Validation.
  • Segments: University, Hospital, Biotech, Pharma, CRO.
  • +400 delegates, +60 speakers confirmed, +100 Posters, 4x Workshops, Network meetings...
  • Venue Site: Øksnehallen, Copenhagen, Denmark.
  • Organiser: CRISPR Medicine News, CMN.
  • Go to the official website here.

Stay tuned for CRISPRMED25, April 7-11 2025 - Sign up to the CRISPRMED25 Newsletter.

Keynote Speaker
Keynote Speaker

Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).

For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.

Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.

Scientific Committee
  • Karen O´Hanlon Cohrt, Chief Editor CRISPR Medicine News, CMN
  • Toni Cathomen, Prof., Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
  • Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
  • Alessia Cavazza, Ass. Prof., Group Leader, University College London's Great Ormond Street Institute of Child Health, England
  • Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
CRISPRMED24 Speakers
  • Alessia Cavazza - Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health, UK
  • Alexandra Madsen - Postdoctoral Fellow at AstraZeneca, Sweden
  • Alvin Luk - Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc., US
  • Andre Cohnen - VP and Head of Genomic Medicine at Bayer Pharmaceuticals, Germany
  • Andrew Bellinger - Chief Scientific Officer and Founder of Verve Therapeutics, Co-Founder at Corner Therapeutics, US
  • Angelo Lombardo - Group Leader at the San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget), Professor at the Vita-Salute San Raffaele University in Milano, Italy, Co-founder of Chroma Medicine, Italy
  • Anna Cereseto - Professor and Vice Director at University of Trento, Co-founder of Alia Therapeutics, Italy
  • Antonio Casini - Co-Founder and CTO at Alia Therapeutics, Italy
  • Ashley Jacobi - Director of Applications & Market Development at Integrated DNA Technologies, US
  • Avencia Sanchez-Mejías - CEO & Co-founder at Integra Therapeutics, Spain
  • Ayal Hendel - Principal Investigator at The Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University, Israel
  • Ben Kleinstiver - Assistant Professor at the Center for Genomic Medicine at Harvard Medical School, MGH Research Scholar at Massachusetts General Hospital, US
  • Bernhard Schmierer - Head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden
  • Brian Cosgrove - Principal Scientist at Tune Therapeutics and the research lead for the Hepatitis B program, US
  • Daniel Schraivogel - Research Staff Scientist at EMBL, Germany
  • Duran Sürün - Postdoctoral Fellow at Dresden University of Technology, Germany
  • Fan Zhou - Senior Scientist within Molecular Biology at GenScript Biotech, US
  • Fiona Behan - Scientific Director at GlaxoSmithKline Pharma, UK
  • Giandomenico Turchiano - Associate Director in Gene Editing Safety at AstraZeneca, Sweden
  • Giulia Hardouin - Postdoctoral Fellow at Imagine Institute of Genetic Diseases, Paris, France
  • Howard Wu - Co-Founder and CSO of Full Circles Therapeutics, as well as the Director of Stellate DNA, US
  • Iván Hernández - CSO of Countagen AB, Sweden
  • Jan Gorodkin - Professor and Group Leader at the University of Copenhagen, Denmark
  • Jan Nelis - Co-Founder and Project Lead at Ariya Bio, Switzerland
  • Jin Chen - Principal Investigator at Altos Labs and an assistant professor at UT Southwestern Medical Center in Dallas, US
  • Jonas Hink - Chief Medical Officer at SNIPR Biome, Denmark
  • Julien Valton - Vice-President of Gene Therapy at Cellectis, France
  • Karim B. El Khlanji - Senior Scientist at the GENyO Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain
  • Karina Thorn - Corporate Vice President, PhD, Head of Research, Global Nucleic Acid Therapies (GNAT) at Novo Nordisk, Denmark
  • Kelly Banas - Principal Investigator at Gene Editing Institute, ChristianaCare, Delaware, US
  • Kevin Holden - Head of Science & Applied Research at Synthego. He is also a Scientific Advisor at Minus, US
  • Kevin Luk - Senior Scientist at Excision BioTherapeutics, US
  • Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, US
  • Laura Torella - Postdoctoral Researcher at CIMA, University of Navarra, Spain
  • Luigi Naldini - M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy, Italy
  • Maaike De Cock - PhD Student at HIV Cure Research Center, Belgium
  • Madelynn Whittaker - Bioengineering PhD Student at the University of Pennsylvania, US
  • Manuel Kaulich - LOEWE-FCI Professor at Goethe University Frankfurt, Chief Scientific Officer at Vivlion, and head of the Frankfurt CRISPR Screening Center, Germany
  • Manuel Rhiel - Postdoctoral Fellow at Institute for Transfusion Medicine and Gene Therapy in the University Medical Centre in Freiburg, Germany
  • Marcello Maresca - Senior Director of Genome Engineering at AstraZeneca, Sweden
  • Maria Silvia Roman Azcona - Postdoctoral Fellow at Institute for Transfusion Medicine and Gene Therapy in the University Medical Centre in Freiburg, Germany
  • Marianne Carlon - Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine, Belgium
  • Michael Krohn - Co-CEO at Akribion Genomics, Germany
  • Nikhil Gupta - Principal Scientist at the Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre, UK
  • Nutsa Burduli - PhD Student at Karolinska Institutet, Sweden
  • Paul Diehl - Chief Operating Officer and Director of Business Development at Cellecta, US
  • Paula M. Cevaal - Research Fellow in infectious diseases at University of Melbourna, Australia
  • Paula Rio - Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid, Spain
  • Pawan Patel - Leader, Northern Europe, Mid-Market Sales at Benchling. Switzerland
  • Pia Johansson - Scientific Coordinator of the Cell and Gene Therapy Core at Lund University, Sweden
  • Raoul Hennig - Head of Manufacturing Site II at BioSpring, Germany
  • Rasmus O. Bak - Tenured Associate Professor at the Department of Biomedicine at Aarhus University, Co-founder of UNIKUM Therapeutics, Denmark
  • Roberto Nitsch - Associate Director of Gene Therapy Safety Group at AstraZeneca, Sweden
  • Samantha Maragh - Leader of the Gene Editing Program at the National Institute of Standards & Technology, US
  • Seung Wook Yang - Principal Scientist at Amgen, US
  • Sidsel Alsing - Field Application Scientist at Samplix, Denmark
  • Simon Reed - Co-Founder and CSO at Broken String Biosciences, UK
  • Simone Spuler - Full Professor at Charité Universistätsmedizin Berlin and a Group Leader at Max Delbrück Center, Germany
  • Stefanie Müthel - Postdoctoral Fellow at Max Delbrück Center, Germany
  • Stefano Stella - Vice-President of Gene Editing at Ensoma, Founder and Chief Technology Officer at Twelve Bio, Ass. Prof. at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark
  • Taejoon Kwon - Associate Professor at Ulsan National Institute of Science and Technology (UNIST), Co-founder at CasCure Therapeutics, S. Korea
  • Thomas W. Skov - PhD Student, Department of Biomedicine, Aarhus University, Denmark
  • Toni Cathomen - Director of the Institute for Transfusion Medicine and Gene Therapy in the University Medical Centre in Freiburg, Professor of Gene and Cell Therapy at the University of Freiburg, Germany
  • Vasileios Georgakakos - Cytogenetics Manager at Clean Cells, France
  • Veronika Jekerle - Head of Pharmaceutical Quality, Human Division, at the European Medicines Agency (EMA), Amsterdam, Netherlands
  • Waseem Qasim - Consultant in Paediatric Immunology and a Prof. of Cell & Gene Therapy at the Infection, Immunity & Inflammation Department at University College London (UCL) Great Ormond Street (GOS) Institute of Child Health, UK
  • Xiaoxia Cui - Director Genome Engineering & Stem Cell Center at Washington University School of Medicine, US
  • Xinlai Cheng - Junior Group Leader in Drug Development at Frankfurt Cancer Institute, Germany
  • Yonglun Luo - Professor in Gene and Stem Cell Technology at the Department of Biomedicine at Aarhus University, Affiliated Researcher at the Steno Diabetes Center in Aarhus, Executive Director at the Lars Bolund Institute of Regenerative Medicine, Denmark
  • Zhenya Ivakine - Group Leader at The Hospital for Sick Children in Toronto, Canada
  • Ziyi Sheng - Student at Center for non-coding RNA in Technology and Health, University of Copenhagen, Denmark
CRISPRMED24 Sponsors and Supporters
CRISPRMED24 Sponsors and Supporters

Attending Institutions and Companies (confirmed)

Attending Institutions and Companies (confirmed)
CRISPRMED24 Sponsors and Supporters
CRISPRMED24 Sponsors and Supporters
close
Search CRISPR Medicine